We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle...
24/02/13 - TSX Venture Exchange Stock Maintenance Bulletins Canada NewsWire VANCOUVER, BC, Feb. 13, 2024 VANCOUVER, BC, Feb. 13, 2024 /CNW/ -TSX VENTURE COMPANIES BULLETIN V2024-0472 HIGH TIDE...
Data support potential for SAT-3247 in multiple degenerative muscle diseases On track to initiate first-in-human clinical trial mid-2024 for Duchenne muscular dystrophy Satellos Bioscience Inc...
Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSXV: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of...
- Company disclosed drug target for Duchenne program; remains on track to initiate clinical trials mid-2024 - Satellos appointed Michael Cross, PhD, MBA, as Chief Business Officer and other key...
Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSXV: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of...
The drug target for the Duchenne program is AAK1, a protein kinase in the Notch pathway, which the Company discovered can be modulated to enable muscle regeneration Satellos is conducting...
Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSXV: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of...
TSX Venture Exchange, Satellos Bioscience Inc., View From The C-Suite Canada NewsWire TORONTO, Aug. 21, 2023 TORONTO, Aug. 21, 2023 /CNW/ - Frank Gleeson, Chief Executive Officer, Satellos...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0.03 | 5.66037735849 | 0.53 | 0.58 | 0.5 | 144102 | 0.53112012 | CS |
26 | 0.18 | 47.3684210526 | 0.38 | 0.61 | 0.29 | 66445 | 0.46913445 | CS |
52 | -0.21 | -27.2727272727 | 0.77 | 0.77 | 0.29 | 78479 | 0.4967122 | CS |
156 | -1.94 | -77.6 | 2.5 | 2.5 | 0.215 | 55799 | 0.63393027 | CS |
260 | -1.94 | -77.6 | 2.5 | 2.5 | 0.215 | 55799 | 0.63393027 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions